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Abstract
This review gives an update of current knowledge on the clinical pleiomorphism of Leishmania, with a special emphasis on the case of
asymptomatic carriage. The ﬁrst part describes the numerous unusual expressions of the disease that occur besides the classic (visceral,
cutaneous, and mucocutaneous) forms of leishmaniases. The second part deals with progress in the understanding of disease outcome
in humans, and the possible future approaches to improve our knowledge in the ﬁeld. The third part highlights the role of the too often
neglected asymptomatic carrier compartment. This group could be key to understanding infraspeciﬁc differences in virulence and patho-
genicity of the parasite, as well as identifying the genetic determinants involved in the expression of the disease.
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Introduction
Infectious diseases remain one of the major challenges in
public health, particularly in developing countries. Neverthe-
less, the causes of the variety of clinical expression in
humans are largely unknown. This is to a great extent
because of the complexity of infectious systems within which
various parameters act and interact: microorganisms, hosts,
vectors (for vector-borne diseases), and environment. Such
an understanding requires study of the diversity, dynamics
and ecology of infectious agents and endemic foci.
For a large number of pathogens, we have only a faint idea
of the biological processes explaining why, in some cases,
there is no disease (asymptomatic carriage) and in others
there is a variety of forms of clinical expression, from benign
to critical forms. This is especially the case for leishmaniases.
Leishmania species, of which there are about 30, can produce
a large spectrum of clinical manifestations in humans, from
asymptomatic to fatal visceral disease, through benign or
conversely severe cutaneous forms; for this reason, the term
is used in the plural. Leishmaniases are widespread in the
world, and still constitute a major public health problem,
causing considerable morbidity and mortality (for further epi-
demiological information, see [1–7]).
The objectives of this review are to give an update of the
knowledge on the clinical pleiomorphism of leishmaniases.
We will also address the question of asymptomatic carriers
(ACs). Indeed, in view of the many aspects of the parasite
cycle, epidemiology and clinical expression of the disease that
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remain unclear, the study of ACs could be a valuable source
of information and understanding. This area, too often
neglected, could constitute a key element in understanding
why some strains are more or less virulent at the infraspe-
ciﬁc level, as well as for identifying the genetic determinants
involved in the expression of the disease. It will also
be essential to better characterize the role that ACs play in
transmission and the consequences of this for control
strategies.
Clinical Diversity and Disease
Complications
Human leishmaniases are classically subdivided into three
main clinical forms: cutaneous, mucocutaneous, and visceral.
Within these three categories, Leishmania infection is able to
produce a large variety of atypical and rare variants. Since
1980, more than 150 papers have been referenced in Pub-
Med reporting unusual clinical presentations, both for the
Old World and the New World.
Cutaneous leishmaniasis (CL) can be the most complex
form to diagnose, as an incredible variety of lesions exists.
CL is classically associated with several species in the Old
World and New World, e.g. Leishmania major, Leishmania
tropica, Leishmania mexicana, Leishmania amazonensis, Leish-
mania braziliensis, Leishmania peruviana, and Leishmania guyan-
ensis (see [5,7–9] for reviews and Table 1). Leishmania
infantum, a classically visceralizing species, also frequently
causes benign cutaneous lesions at the biting site of the sand-
ﬂy [10,11], at a ratio of at least one CL case for one visceral
leishmaniasis (VL) case in France, which is probably an
underestimate (L. Lachaud and P. Bastien, unpublished data
from the national notiﬁcation system); the same has been
described in Central America for its synonym Leishmania
chagasi [11] and, to a much lesser extent, for Leishmania
donovani in Sri Lanka [12] and in Yemen [13]. L. donovani also
produces a particular cutaneous disease termed post-kala
azar dermal leishmaniasis (PKDL) (see below). CL occurs in
humans as a localized or diffuse form, depending on the
infecting species of Leishmania [8,14,15] (Table 1) and human
host factors (reviewed in [16]). The typical and most com-
mon CL lesion is a torpid self-healing round ulcer, leaving an
ineradicable and unattractive scar with sometimes dramatic
social consequences. However, lesions can be highly poly-
morphic, and, apart from the ‘classic’ ulcer, frequently appear
as single crusted papules (‘uta’), verrucous or papulonodular.
Necrosis of the external ear caused by L. mexicana (‘chiclero’
ulcer) and sporotrichoid lesions caused by L. guyanensis
(‘pian-bois’) have also been well described (reviewed in
TABLE 1. Main Leishmania species associated with different clinical outcomes in leishmaniases
Cutaneous leishmaniasis
Mucocutaneous
leishmaniasis
Visceral
leishmaniasis
Main clinical form L. major
L. tropica
L. killicki
L. aethiopica
L. mexicana
L. amazonensis
L. braziliensis
L. peruviana
L. guyanensis
L. infantuma
L. shawia
L. naifﬁa
L. lainsonia
L. donovanib
L. braziliensis
L. panamensisa
L. amazonensisa
L. guyanensisb
L. donovani
L. infantum/chagasi
L. tropicab
Particular forms of
cutaneous disease
L. donovani: PKDL
L. mexicana: ‘chiclero ulcer’
L. peruviana: ‘uta’
L. guyanensis: ‘pian-bois’
L. aethiopicaa, L. mexicanaa, L. amazonensisa: DCL
L. tropicaa, L. aethiopicaa, L. braziliensisb, L. panamensisb,
L. guyanensisb, L. amazonensisb: recidivans and disseminated
leishmaniasis
Immunosuppressed
patients (mainly
HIV-positive
patients)
Most species L. donovania
L. infantumb,c
L. majorb,d
L. guyanensisb
L. amazonensisb
L. infantumc
L. braziliensisb
L. mexicanab
L. amazonensisb
DCL, disseminated cutaneous leishmaniasis; HIV, human immunodeﬁciency virus; PKDL, post kala-azar dermal leishmaniasis.
aRarely. bExceptionally. cIncluding ‘dermotropic’ zymodemes. dLocal extension to the mucosa.
Bibliographic references can be found in the text.
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[8,17]). Besides these well-known presentations, numerous
unusual variants associated with many different species have
been reported, described as ‘eczematoid’, ‘inﬁltrative pla-
ques’, ‘paronychial’, ‘chancriform’, ‘erysipeloid’, ‘zosteriform’,
‘lupoid’, ‘whitlow’, ‘sprototrichoid’, etc. [9,18–25].
Classically, in most cases, cutaneous lesions appear at the
site of the sandﬂy bite. Thus, all exposed parts of the body
are susceptible to cutaneous lesions. Nevertheless, unusual
locations, such as genital organs and palms, have been
observed [26–30]. Furthermore, multiple lesions are fre-
quently observed, possibly owing to multiple inoculations
[31–33]. With respect to disease evolution, CL may reappear
as satellite lesions along the route of lymphatic drainage or,
in rare cases, progress around the site of the original lesion
as recidivans leishmaniasis [25,34,35], or, even worse, evolve
towards disseminated CL; all of these are clinically and epide-
miologically well-described forms [17,36,37]. Disseminated
CL is essentially caused by Leishmania aethiopica in East Africa
and L. amazonensis and L. mexicana in South America
(Table 1); it produces diffuse, non-ulcerated nodular lesions
that fail to heal spontaneously, relapse after treatment, and
may generalize to the whole body, leaving highly unsightly
scars and sometimes causing death [9]. This form has been
also associated with human immunodeﬁciency virus (HIV)
co-infection and with the immune reconstitution inﬂamma-
tory syndrome (IRIS), but is caused by unusual Leishmania
species [28,38–40]. PKDL is a particular evolution of VL
caused by L. donovani that develops in spite of a successful
primary response to therapy, usually 1–2 years after appar-
ent clinical cure [36,41]. It presents as hypopigmented ma-
cules, papules, nodules, or facial erythema. PKDL has been
reported in 50–60% and 5–10% of VL patients in Sudan and
the Indian subcontinent, respectively [41].
With this high number of non-speciﬁc and atypical presen-
tations, CL often mimics other infectious diseases and can-
cers (see [28,42,43] for examples), leading to misdiagnosis
and delay in starting treatment.
Mucocutaneous leishmaniasis (MCL), the other prominent
clinical manifestation of New World tegumentary leishmani-
asis, is also known as ‘espundia’, and is essentially associ-
ated with L. braziliensis; rare forms have been observed
with Leishmania panamensis, and exceptionally with L. guyan-
ensis and L. amazonensis (reviewed in [5,8,44–46]). It causes
extensive destruction of oronasal and pharyngeal cavities,
with hideously disﬁguring lesions, mutilation of the face, and
great life-long distress for the patient. Although the nose
mucosa is the preferred site for MCL (90% of mucosal
lesions), the lips, palate, mouth, pharynx and larynx can also
be affected, as well as the middle ear [47–50]. Mucosal
involvement is usually metastatic, i.e. secondary, several
years after cutaneous lesions [37], although cases have been
reported where the mucosa was the primary site [48].
Dissemination from cutaneous to mucosal lesions appears
to take place through the lymphatic system or blood ves-
sels, but rarely (if ever) by direct contact between the
mucosa and the cutaneous lesions [48]. In the Old World,
MCL has rarely been observed in Sudan and North Africa,
where leishmaniases result from either direct inoculation of
the parasites in the mucosa or from local extension of the
cutaneous lesions to the mucosa [9]. Finally, there are
rare reports of mucosal involvement with L. infantum or
dermotropic species in immunosuppressed patients [37,51]
(Table 1).
VL, also called kala-azar in the Indian subcontinent, is the
most severe form of leishmaniasis, as it is fatal if left
untreated. It is estimated that VL causes over 50 000 deaths
annually, a rate surpassed among parasitic diseases only by
malaria [1]. It is characterized by undulating fever, loss of
weight, hepatosplenomegaly and/or lymphadenopathies, and
pancytopenia, particularly anaemia. This form is generally
caused by L. donovani senso lato, including L. infantum/L. chagasi
(Table 1). Whereas L. infantum is essentially a parasite caus-
ing zoonotic disease, mainly in dogs, and is responsible for
low endemicity with regard to humans, L. donovani is human-
speciﬁc and may be responsible for large-scale epidemics
with a high fatality rate [37,52–55] (see also [7], this issue).
Some ‘unorthodox’ expressions of the disease result from a
peculiar presentation of classically visceralizing species (the
L. donovani complex). For example, as described above,
L. infantum, which is classically responsible for VL and local-
ized CL, has been described as causing purely mucocutane-
ous leishmaniasis (see examples in [51,56]). In contrast,
visceralization of Leishmania species considered to be dermo-
tropic has been observed [46,57,58] (Table 1).
The number of atypical presentations reported with ‘vis-
ceral’ species has been growing with the increasing frequency
of immunosuppression, showing the essential role of immune
control in the expression of the disease. For example, a case
of pseudotumoral-like recurrence located in the nasal
mucous membrane 4 years after a classic VL episode caused
by L. infantum was observed in a 7-year-old girl treated with
anti-tumour necrosis factor and steroids [59].
The clinical manifestations are particularly diverse during
Leishmania–HIV co-infection, where VL has emerged as an
important opportunistic infection. In AIDS patients, VL usu-
ally has atypical presentations, often severe but also fre-
quently attenuated, both clinically and biologically, making
the diagnosis difﬁcult for practitioners (reviewed in [60,61]).
In particular, numerous unusual locations of the parasite
have been described (reviewed in [28]). Most importantly,
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it follows a relapsing course that may last for years, the
relapse risk depending on the CD4+ T-cell levels [28,61–
63]. Thus, a novel nosological entity termed ‘active chronic
visceral leishmaniasis’ has been proposed for immunocom-
promised patients presenting with continuous blood circula-
tion of the parasite associated with numerous secondary
VL episodes despite both preventive and curative treatment
[64].
Although Leishmania–HIV co-infection concerns mainly
VL, several cases of CL have been reported from different
countries (reviewed in [28]). L. braziliensis, L. mexicana, and
L. amazonensis, as well as dermotropic isoenzymatic variants
of L. infantum, have been reported to cause visceral disease
in HIV-positive patients [28] (Table 1). Cutaneous involve-
ment has been reported to occur in 8–12% of patients
with Leishmania–HIV co-infection [28]. It is worth noting
that these patients may present highly polymorphic lesions
(papulonodular, ulcerative, inﬁltrative, lepromatous and dif-
fuse, psoriasis-like, cheloid, histioid, or Kaposi’s sarcoma-
like) at the same time. Some patterns of presentation share
similarities with other speciﬁc infections, such as dissemi-
nated or extrapulmonary coccidioidomycosis or histoplas-
mosis [28].
Finally, the asymptomatic forms of leishmaniasis proba-
bly constitute a further and extreme example of clinical
diversity, as will be examined in the third part of this
review.
Our present knowledge of Leishmania tropism in humans
is largely inﬂuenced by the fact that clinical diagnosis is based
on the sampling of deﬁned body tissues, which are primarily
microscopically examined (usually, bone marrow, lymph
nodes and spleen for VL, and cutaneous lesions for CL). The
introduction of PCR in the 1990s has modiﬁed our views
regarding tropism, particularly if an ‘ultrasensitive’ PCR assay
is used [65]. For example, except for rare reports [66–68],
blood circulation of L. infantum in humans was largely unsus-
pected before the application of PCR in 1995 [69]. Similarly,
delayed and/or ‘non-classic’ clinical forms suggest that the
parasites’ distribution in the body extends beyond the appar-
ently affected tissues, e.g. to the healthy skin, from where
they can be more easily detected in case of immunodeﬁ-
ciency, as was demonstrated experimentally in a murine
model [70]. Also, the common view that L. infantum is vis-
cerotropic may be contradicted by the fact that the parasite
massively invades the skin in the dog reservoir [65]. Thus,
the issue of pathogen tropism in leishmaniases remains a
topical debate [71], as it depends upon both parasite features
[72,73] and immunogenetics of the host (see below), proba-
bly in inﬁnitely variable proportions (see Supporting Informa-
tion, Fig. S1).
Scientiﬁc Progress on the Clinical
Pleiomorphism of Leishmaniases:
Experimental, Mechanistic and Genetic
Aspects
Disease manifestations of infections in humans depend on
multifactorial parameters, such as host response or suscepti-
bility, parasite genetic background, and, potentially, factors
depending on the vector (see Supporting Information,
Fig. S1). Indeed, the different clinical forms are closely
related to the adaptive immune response of the host. The
nature of the pathogen, notably the species but also at the
infraspeciﬁc level, seems to be a strong factor as well
(Table 1). How Leishmania species cause human diseases and
why the clinical symptoms are so variable remain unclear.
Concerning the human host response, different patterns
of immunological response are observed, according to the
clinical manifestation and exposure to different Leishmania
species. Resistance and susceptibility to Leishmania infection
have been associated with the generation of T-helper (Th)1
and Th2 responses, respectively. This infectious disease
model was later used to identify and assess the role of key
factors, such as interleukin-12 and interleukin-4, in Th1 and
Th2 maturation [74]. Nylen and Gautam [75] recently
reviewed this issue, and showed that, although still valid in
several respects, the Th1/Th2 paradigm is an oversimpliﬁca-
tion. Numerous studies have demonstrated that a number of
other T-cell subsets, including regulatory T-cells and Th17
cells, alo have important roles in susceptibility and resistance
to both experimental and human leishmanial disease.
Although there is certainly much more to explore regard-
ing purely immune response mechanisms, in our view, the
main research ﬁeld to develop in this scientiﬁc area com-
prises the interactions between Leishmania and its insect and
mammalian hosts. One promising approach is the study of
immune evasion mechanisms that allow parasites to avoid
the development of sterilizing immunity and secure their
transmission to a new host (reviewed in [74]). The impor-
tance of these processes has been known for a long time for
many pathogens [76], and also for Leishmania [77]. This sug-
gests that it is crucial to identify the diverse mechanisms by
which these agents modulate or evade their hosts’ defences,
creating a dynamic interplay between the human immune
system and the parasite population. For example, a recent
study using L. amazonensis and L. braziliensis (species that are
usually able to produce infection or only transient self-heal-
ing cutaneous lesions in BALB/c mice) clearly showed that it
is the involvement of parasite molecules, the immune
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response and the host genetic background together that
determines the disease outcome [78]. The same close inter-
play between host, parasite and vector-dependent factors
was shown for human VL in Sudan [79]. Nevertheless, studies
focusing on speciﬁc factors are necessary to target the main
processes involved in pathogenesis. For example, the analysis
of leishmaniasis symptomatology in mice by monitoring skin
lesions, hepatosplenomegaly and seven immunological param-
eters allowed the detection and mapping of 17 L. major
response (Lmr) gene loci that control the symptoms of infec-
tion [80]. To directly identify the potential genes involved in
human diseases, several studies genetically compared popula-
tions presenting different evolution patterns of leishmaniasis.
Some studies identiﬁed signiﬁcant associations between
human gene polymorphisms and expression of the disease,
such as the regulatory CCL2 (coding for proinﬂammatory
monocyte chemoattractant protein 1) promoter polymor-
phism for MCL/CL differentiation [81], and other genetic
polymorphisms for VL or CL involvement [79,82–88].
With respect to the role of Leishmania parasite diversity
on disease manifestations, it is evident that each Leishmania
species has its own tropism and speciﬁc clinical forms (for
example, L. tropica is well known to produce more severe
lesions that heal less rapidly than those caused by L. major).
Even at the infraspeciﬁc level, numerous studies have shown
the role played by the parasitic strains in the outcome of the
disease (reviewed in [5]). As an additional example, Alimo-
hammadian et al. [89] reported that different genetic strains
of L. major isolated from distinct endemic areas in Iran were
able to cause major differences in parasite load and immuno-
genicity of susceptible BALB/c mice. Nevertheless, more
work is required to relate the immune responses in mice to
those in human and canine infections. On the genetic side,
several studies have linked genetic polymorphisms to the
tropism observed in humans or to immune evasion [90–94].
Besides these speciﬁc studies, sequencing of the whole ge-
nomes of L. major, L. braziliensis and L. infantum will provide
interesting insights into disease phenotype at the global level.
Surprisingly, the Leishmania genome is highly conserved, and
has <1% of species-speciﬁc genes [95]. These genes mainly
encode proteins involved in host–pathogen interactions and
parasite survival in the macrophage. Thus, they might be
good candidates for functional analysis to determine their
roles in the establishment of infection or speciﬁc disease
manifestations (see Supporting Information, Fig. S2) [96]. The
low level of differentiation between the genomes and gene
expression suggests that studies of expressed proteins in the
amastigote (vertebrate) life-cycle stage of the parasite are
crucial [97]. Because there seems to be no regulation of
gene expression at the transcriptional level in these parasites
[98], these proteins are likely to be regulated at the level of
translation control or protein stability; hence, studies need
to also focus on protein modiﬁcations and how they affect
disease pathogenicity. Finally, epigenetic regulation is not well
known in Leishmania, but certainly adds more complexity to
the role played by the parasite [99].
In addition, extrinsic factors may inﬂuence the course of
infection. For example, the nature of the sandﬂy bite itself has
become a tremendously important parameter of infection.
Multiple cutaneous lesions are, in part, caused by the inability
of the vector to feed when its ‘oesophagus’ is blocked by an
accumulation of parasites ﬁxed upon the stomodeal valve
[100]. The exacerbation of the establishment and develop-
ment of CL by sandﬂy saliva, owing to its immunomodulatory
properties, has long been documented for several Leishmania
species [101]. However, this is complicated by the discovery
that previous exposure to salivary components can have a
protective effect against Leismania infection [102]. More
recently, another natural component regurgitated by the ﬂy,
consisting of a proteophosphoglycan-rich gel secreted by the
parasite inside the midgut, was also shown to beneﬁt the
establishment of VL caused by L. infantum [103]. Finally,
another recent study has opened new and amazing research
perspectives: Ives et al. [104] showed that Leishmania RNA
viruses could control the severity of MCL. More speciﬁcally,
recognition of the virus within metastasizing L. guyanensis par-
asites by the host promoted inﬂammation and subverted the
immune response to promote parasite persistence.
All of these data show that we are still far from under-
standing all of the mechanisms underlying Leishmania infection
outcome (see Supporting Information, Fig. S1). In our view,
asymptomatic carriage may also be a fundamental aspect to
study in order to achieve progress in our knowledge of dis-
ease expression.
The Asymptomatic Compartment: a Key
Element in the Understanding of
Pathogenesis and Epidemiology?
AC is used in this review to deﬁne mammalian hosts infected
with Leishmania parasites but that do not show any sign of
disease. Identiﬁcation of an AC is not easy, as one may con-
sider that only conventional methods, such as microscopic
observation and parasite cultivation, can provide a deﬁnite
diagnosis, as immunological or molecular techniques, such as
PCR, do not demonstrate the presence of live parasitic cells.
Nevertheless, recent studies showed that Leishmania nucleic
acids detected by PCR came from live parasites and were
rapidly degraded following parasite death [105,106].
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For many infectious diseases, ACs constitute a key point in
transmission, and also in the evolution from the asymptomatic
to the patent stage. ACs may never develop the disease, or
the asymptomatic carriage may be a temporary stage before
the development of clinical signs [107,108]. There are numer-
ous examples of ACs with bacteria, viruses, or parasites [109–
112]. Numerous reports (see below) support the existence of
asymptomatic leishmaniasis in animals as well as in humans.
Failures of certain control programmes suggest that the elimi-
nation of the seropositive or clinically ill reservoir is not
enough to stop transmission. For example, the elimination of
such patently infected dogs in Brazil has failed to stop or pre-
vent epidemics of urban VL caused by L. infantum, suggesting
that other secondary (asymptomatic) reservoirs may be impor-
tant in propagating the infection [113–116]. Moreover, various
authors have shown that asymptomatic dogs can be infective
to the sandﬂy vectors, just like symptomatic dogs [117–119].
Thus, as the natural reservoir hosts of Leishmania often remain
asymptomatic [120], it is now essential to investigate the
potential role of ACs in the maintenance of transmission in
leishmaniasis foci. Epidemiological studies using different tools
have demonstrated that variable percentages of human ACs of
L. infantum exist in the Mediterranean area, e.g. 4% in north-
western Italy [121], 3% in Monaco [122], 22% in the Balearic
Islands [123], 24% in Iran [124], and 58% in southern France
[125] and, among HIV-infected subjects, 30% in Spain [126],
but 0.03% [127] in western Sicily and 16% [128] in Palermo
area, Sicily. In the highly endemic state of Bihar, India, a recent
study estimated the number of asymptomatic seropositive sub-
jects in the population without a history of VL to be almost
13%, suggesting a high rate of ACs also with L. donovani [129].
Asymptomatic Leishmania-infected dogs have become the sub-
ject of sustained interest, with a median ten-fold increase in
the number of yearly publications on the subject since the
report of the ﬁrst PCR diagnostic ﬁeld studies [65,130,131].
Indeed, 65% of asymptomatic dogs in southern France, 60% in
Spain [131] and between 22% and 80% in southern Italy
[65,107,130,132] have been found to harbour blood-circulating
parasites by PCR. The variable prevalence rates between stud-
ies in countries of similar epidemiology are probably attribut-
able to the highly variable performances of the diagnostic
methods used, particularly for serology and PCR [125,133–
137]. Although PCR methods, particularly the ‘ultrasensitive’
ones used in most of these studies, may always be suspected
of yielding a proportion of false-positive results, the body of
evidence is sufﬁcient to believe that the number of ACs of
visceralizing Leishmania is larger than that of hosts presenting
with patent disease.
The relatively recent discovery of the importance of ACs
in VL poses a number of interesting questions. The ﬁrst
concerns the issue of disease risk resulting from blood trans-
fusion from asymptomatic donors. The possibility of leishman-
iasis transmission from an asymptomatic blood donor exists
[138–142], and the risks to public health deserve to be
assessed [143]. In France, there is no blood screening for
Leishmania, even in the south, where L. infantum is endemic;
but the French Institute for Public Health Surveillance esti-
mates that the leukodepletion almost completely rules out
the risk of transmission [143], and this was conﬁrmed by the
work of Riera et al. [144] in the Balearic Islands. Also, classic
pathogen inactivation of blood concentrates proved to be efﬁ-
cient against Leishmania parasites [145]. Nevertheless, the risk
might be critical for immunocompromised patients, who are
more likely to develop the disease. In southern Europe, a
considerable proportion of HIV-infected patients are ACs of
L. infantum [28,123,126]. VL is also frequently observed in
other immunosuppressed patients, such as graft recipients,
those with blood cancers, and those undergoing long-term
steroid treatment [146–148]. It therefore appears essential to
deﬁne worldwide common recommendations to screen for
ACs in VL-endemic areas.
Another interesting question is the possible cause of
asymptomatic carriage. We know very little of the relative
contributions of the host, the parasite or any other factor in
the evolution of Leishmania infection towards an asymptom-
atic outcome. Considering the host, there are numerous
studies showing that host factors are crucial for infection evo-
lution. Nevertheless, the factors determining the host resis-
tant/susceptible status appear to be complex, and are mostly
unknown. In endemic areas, it is striking to observe, for a
given parasite species, a wide range of inter-individual variabil-
ity in susceptibility/resistance to disease (reviewed in [16]). In
contrast with ACs, some subjects are unable to control para-
site dissemination and/or multiplication, and develop clinical
symptoms of diverse severity. The general state of health and
physiological condition of the host, in particular subtle immu-
nity variations, do inﬂuence disease progression, as shown,
for example, by the classically higher incidence of L. infantum
VL in infants and elderly people [9,149,150]. Nutritional state
is also an essential factor, as shown by the devastating VL epi-
demics that took place in refugee populations in Sudan in the
years 1984–1994, 1997, and 2009 [53,151,152]. Genetic pre-
disposition also undoubtedly plays a major role in determining
disease outcomes [16]. Profound ethnic differences in the
ratio of asymptomatic to symptomatic infections have been
observed [86,153], and, as described above, certain genes
have been incriminated in the susceptibility to visceral disease.
All in all, it is most likely that asymptomatic carriage is
strongly mediated by nutritional, physiological and immunoge-
netic host factors (see Supporting Information, Fig. S1).
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The parasite itself might provide another clue to the
absence of symptoms. Speciﬁc clinical features are grossly
associated with particular Leishmania species, but we do not
know whether the parasite or the host determines the dif-
ferent clinical forms encountered for the same species (see
Supporting Information, Fig. S1; Table 1). Similarly, particular
strains might be less virulent than others, i.e. less able to
cause patent disease. Very little is known about the Leish-
mania strains associated with asymptomatic carriage, in great
part because of the difﬁculty in isolating them in vitro. We
recently demonstrated that Leishmania isolates obtained from
ACs in France are genetically different from those obtained
from patients with VL or CL (M. Hide, E. Marion, P. Marty,
R. Fisa, A.L. Ban˜uls, in preparation). This observation opens a
large study area, suggesting the possibility of identifying genes
or genotypes involved in asymptomatic vs. symptomatic dis-
ease outcomes. To better understand the mechanisms
involved in leishmaniasis (whether VL, CL, or MCL) patho-
genesis and immunity, it now appears essential to include
strains from ACs with the classic symptomatic strains in all
studies of host immune response, pathogenicity, gene
expression, etc. However, isolating a representative sample
number of these strains remains a major problem.
In summary, besides the three classic categories of leish-
maniasis (CL, VL, and MCL), the clinical expression of the
disease is highly polymorphic, depending on both the host
and the parasite, and, for the latter, at the species, infraspe-
ciﬁc and probably ‘individual’ (strain) levels. Leaving aside the
difﬁculties in patient care caused by such pleiomorphism, the
role of ACs needs to be explored to obtain a better
understanding of the molecular cellular and immune mecha-
nisms underlying pathogenicity and progression of the infec-
tion outcome. The exploration of the subtle variations in
hosts and parasites that determine these differences poses
challenges similar to those of ‘personalized medicine’, and
promises to be an exciting venture for the coming years.
Acknowledgements
The authors acknowledge P. Marty and J. P. Dedet for helpful
discussions. The genetic comparison of Leishmania strains iso-
lated from ACs with those isolated from VL or CL patients
was funded by the MIE CNRS programme.
Transparency Declaration
We received no grants or ﬁnancial support for the prepara-
tion of this manuscript and have no conﬂict of interest.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Fig. S1. Factors acting on the clinical pleiomorphism of
leishmaniases in humans. Leishmania infection is able to pro-
duce a large variety of clinical expressions in humans. This is,
to a large extent, because of the complexity of infectious
systems within which various factors act and interact: micro-
organisms, hosts, vectors, and environment.
Fig. S2. Species-speciﬁc genes in Leishmania. The Venn
diagram shows how many of the 8187 protein-coding genes
are species-speciﬁc or shared between two of the three
sequenced Leishmania species. These genes are subdivided
into those that have a predicted function (mostly through
sequence identity) and those that are of unknown function
at the time of publication (‘hypotheticals’).
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials supplied
by the authors. Any queries (other than missing material)
should be directed to the corresponding author for the
article.
References
1. World Health Organization. Control of the leishmaniases. Report
No. 949. WHO, 2011. .
2. Desjeux P. Leishmaniasis: current situation and new perspectives.
Comp Immunol Microbiol Infect Dis 2004; 27: 305–318.
3. Ezra N, Ochoa MT, Craft N. Human immunodeﬁciency virus and
leishmaniasis. J Glob Infect Dis 2010; 2: 248–257.
4. Cruz I, Nieto J, Moreno J, Canavate C, Desjeux P, Alvar J. Leish-
mania/HIV co-infections in the second decade. Indian J Med Res
2006; 123: 357–388.
5. Ban˜uls AL, Hide M, Prugnolle F. Leishmania and the leishmaniases: a
parasite genetic update and advances in taxonomy, epidemiology and
pathogenicity in humans. Adv Parasitol 2007; 64: 1–109.
6. Bastien P. Leishmaniases control: what part for development and
what part for research? Clin Microbiol Infect 2011; 17: 1449–1450.
7. den Boer M, Argaw D, Jannin J, Alvar J. Leishmaniasis impact and
treatment access. Clin Microbiol Infect 2011; 17: 1471–1477.
8. Ameen M. Cutaneous leishmaniasis: advances in disease pathogenesis,
diagnostics and therapeutics. Clin Exp Dermatol 2010; 35: 699–705.
9. Dedet J, Pratlong F. Leishmaniasis. In: Cook G, Zumla A, eds. Man-
son’s tropical diseases, 22nd edn. Philadelphia, PA: Saunders, 2009;
1341–1365.
10. Dedet JP, Pratlong F, Lanotte G, Ravel C. Cutaneous leishmaniasis.
The parasite. Clin Dermatol 1999; 17: 261–268.
11. Ponce C, Ponce E, Morrison A et al. Leishmania donovani chagasi:
new clinical variant of cutaneous leishmaniasis in Honduras. Lancet
1991; 337: 67–70.
12. Karunaweera ND. Leishmania donovani causing cutaneous leishmania-
sis in Sri Lanka: a wolf in sheep’s clothing? Trends Parasitol 2009; 25:
458–463.
CMI Ban˜uls et al. Leishmaniases and clinical pleiomorphism 1457
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1451–1461
13. Pratlong F, Bastien P, Perello R, Lami P, Dedet JP. Human cutaneous
leishmaniasis caused by Leishmania donovani sensu stricto in Yemen.
Trans R Soc Trop Med Hyg 1995; 89: 398–399.
14. Akilov OE, Khachemoune A, Hasan T. Clinical manifestations and
classiﬁcation of Old World cutaneous leishmaniasis. Int J Dermatol
2007; 46: 132–142.
15. Hepburn NC. Cutaneous leishmaniasis: an overview. J Postgrad Med
2003; 49: 50–54.
16. Hide M, Bucheton B, Kamhawi S et al. Understanding human leish-
maniasis: the need for an integrated approach. In: Tibayrenc M, ed.
Encyclopedic guide to infectious disease research: modern methodologies.
Hoboken: Wiley, 2007; 87–123.
17. Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous
and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 2010; 8:
419–433.
18. Karincaoglu Y, Esrefoglu M, Ozcan H. Atypical clinical form of cuta-
neous leishmaniasis: erysipeloid form. Int J Dermatol 2004; 43: 827–
829.
19. Iftikhar N, Bari I, Ejaz A. Rare variants of cutaneous leishmaniasis:
whitlow, paronychia, and sporotrichoid. Int J Dermatol 2003; 42:
807–809.
20. Raja KM, Khan AA, Hameed A, Rahman SB. Unusual clinical variants of
cutaneous leishmaniasis in Pakistan. Br J Dermatol 1998; 139: 111–113.
21. Bari AU, Rahman SB. Many faces of cutaneous leishmaniasis. Indian J
Dermatol Venereol Leprol 2008; 74: 23–27.
22. Bari A, Bari A, Ejaz A. Fissure leishmaniasis: a new variant of cutane-
ous leishmaniasis. Dermatol Online J 2009; 15: 13.
23. Guimaraes LH, Machado PR, Lago EL et al. Atypical manifestations
of tegumentary leishmaniasis in a transmission area of Leishmania
braziliensis in the state of Bahia, Brazil. Trans R Soc Trop Med Hyg
2009; 103: 712–715.
24. Padovese V, Terranova M, Toma L, Barnabas GA, Morrone A. Cuta-
neous and mucocutaneous leishmaniasis in Tigray, northern Ethiopia:
clinical aspects and therapeutic concerns. Trans R Soc Trop Med Hyg
2009; 103: 707–711.
25. Kubba R, el-Hassan AM, Al-Gindan Y, Omer AH, Kutty MK, Saeed
MB. Dissemination in cutaneous leishmaniasis. I. Subcutaneous nod-
ules. Int J Dermatol 1987; 26: 300–304.
26. Lindoso JA, Barbosa RN, Posada-Vergara MP et al. Unusual manifes-
tations of tegumentary leishmaniasis in AIDS patients from the New
World. Br J Dermatol 2009; 160: 311–318.
27. Cabello I, Caraballo A, Millan Y. Leishmaniasis in the genital area.
Rev Inst Med Trop Sao Paulo 2002; 44: 105–107.
28. Alvar J, Aparicio P, Aseffa A et al. The relationship between leish-
maniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21:
334–359.
29. White SW, Hendricks LD. American cutaneous leishmaniasis. Int J
Dermatol 1982; 21: 86–88.
30. Colebunders R, Depraetere K, Verstraeten T et al. Unusual cutane-
ous lesions in two patients with visceral leishmaniasis and HIV infec-
tion. J Am Acad Dermatol 1999; 41: 847–850.
31. Shani-Adir A, Kamil S, Rozenman D et al. Leishmania tropica in north-
ern Israel: a clinical overview of an emerging focus. J Am Acad Der-
matol 2005; 53: 810–815.
32. Faye B, Ban˜uls AL, Bucheton B et al. Canine visceral leishmaniasis
caused by Leishmania infantum in Senegal: risk of emergence in
humans? Microbes Infect 2010; 12: 1219–1225.
33. Samaranayake TN, Dissanayake VH, Fernando SD. Clinical manifesta-
tions of cutaneous leishmaniasis in Sri Lanka—possible evidence for
genetic susceptibility among the Sinhalese. Ann Trop Med Parasitol
2008; 102: 383–390.
34. Calvopina M, Uezato H, Gomez EA, Korenaga M, Nonaka S, Hashig-
uchi Y. Leishmaniasis recidiva cutis due to Leishmania (Viannia) pan-
amensis in subtropical Ecuador: isoenzymatic characterization. Int J
Dermatol 2006; 45: 116–120.
35. Kubba R, al-Gindan Y, el-Hassan AM, Omer AH, Kutty MK, Saeed
MB. Dissemination in cutaneous leishmaniasis. II. Satellite papules
and subcutaneous induration. Int J Dermatol 1988; 27: 702–706.
36. Grevelink SA, Lerner EA. Leishmaniasis. J Am Acad Dermatol 1996;
34: 257–272.
37. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leish-
maniasis. Lancet 2005; 366: 1561–1577.
38. Sinha S, Fernandez G, Kapila R, Lambert WC, Schwartz RA. Diffuse
cutaneous leishmaniasis associated with the immune reconstitution
inﬂammatory syndrome. Int J Dermatol 2008; 47: 1263–1270.
39. Couppie P, Clyti E, Sobesky M et al. Comparative study of cutane-
ous leishmaniasis in human immunodeﬁciency virus (HIV)-infected
patients and non-HIV-infected patients in French Guiana. Br J Derma-
tol 2004; 151: 1165–1171.
40. Rosatelli JB, Souza CS, Soares FA, Foss NT, Roselino AM. General-
ized cutaneous leishmaniasis in acquired immunodeﬁciency syn-
drome. J Eur Acad Dermatol Venereol 1998; 10: 229–232.
41. Ganguly S, Das NK, Barbhuiya JN, Chatterjee M. Post-kala-azar
dermal leishmaniasis—an overview. Int J Dermatol 2010; 49: 921–
931.
42. Veraldi S, Bottini S, Curro N, Gianotti R. Leishmaniasis of the eyelid
mimicking an infundibular cyst and review of the literature on ocular
leishmaniasis. Int J Infect Dis 2010; 14 (suppl 3): e230–e232.
43. Zeegelaar JE, Faber WR. Imported tropical infectious ulcers in trav-
elers. Am J Clin Dermatol 2008; 9: 219–232.
44. Tojal da Silva AC, Cupolillo E, Volpini AC, Almeida R, Romero GA.
Species diversity causing human cutaneous leishmaniasis in Rio
Branco, state of Acre, Brazil. Trop Med Int Health 2006; 11: 1388–
1398.
45. Guerra JA, Prestes SR, Silveira H et al. Mucosal leishmaniasis caused
by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis
in the Brazilian Amazon. PLoS Negl Trop Dis 2011; 5: e980.
46. Barral A, Pedral-Sampaio D, Grimaldi Junior G et al. Leishmaniasis in
Bahia, Brazil: evidence that Leishmania amazonensis produces a
wide spectrum of clinical disease. Am J Trop Med Hyg 1991; 44: 536–
546.
47. Casero R, Laconte L, Fraenza L, Iglesias N, Quinteros Greco C, Vil-
lablanca M. Recidivant laryngeal leishmaniasis: an unusual case in an
immunocompetent patient treated with corticosteroids. Rev Argent
Microbiol 2010; 42: 118–121.
48. Lessa MM, Lessa HA, Castro TW et al. Mucosal leishmaniasis: epide-
miological and clinical aspects. Braz J Otorhinolaryngol 2007; 73: 843–
847.
49. Motta AC, Arruda D, Souza CS, Foss NT. Disseminated mucocuta-
neous leishmaniasis resulting from chronic use of corticosteroid. Int
J Dermatol 2003; 42: 703–706.
50. Motta AC, Lopes MA, Ito FA, Carlos-Bregni R, de Almeida OP,
Roselino AM. Oral leishmaniasis: a clinicopathological study of 11
cases. Oral Dis 2007; 13: 335–340.
51. Faucher B, Pomares C, Fourcade S et al. Mucosal Leishmania infantum
leishmaniasis: speciﬁc pattern in a multicentre survey and historical
cases. J Infect 2011; 63: 76–82.
52. John TJ, Dandona L, Sharma VP, Kakkar M. Continuing challenge of
infectious diseases in India. Lancet 2011; 377: 252–269.
53. Seaman J, Mercer AJ, Sondorp E. The epidemic of visceral leishmani-
asis in western Upper Nile, southern Sudan: course and impact from
1984 to 1994. Int J Epidemiol 1996; 25: 862–871.
54. Nasereddin A, Baneth G, Schonian G, Kanaan M, Jaffe CL. Molecular
ﬁngerprinting of Leishmania infantum strains following an outbreak of
visceral leishmaniasis in central Israel. J Clin Microbiol 2005; 43:
6054–6059.
1458 Clinical Microbiology and Infection, Volume 17 Number 10, October 2011 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1451–1461
55. Postigo JA. Leishmaniasis in the World Health Organization Eastern
Mediterranean Region. Int J Antimicrob Agents 2010; 36 (suppl 1):
S62–S65.
56. Herwaldt BL. Leishmaniasis. Lancet 1999; 354: 1191–1199.
57. Magill AJ, Grogl M, Gasser RA Jr, Sun W, Oster CN. Visceral infec-
tion caused by Leishmania tropica in veterans of Operation Desert
Storm. N Engl J Med 1993; 328: 1383–1387.
58. Hernandez DE, Oliver M, Martinez C, Planas G. Visceral leishmania-
sis with cutaneous and rectal dissemination due to Leishmania brazili-
ensis in acquired immunodeﬁciency syndrome (AIDS). Int J Dermatol
1995; 34: 114–115.
59. Jeziorski E, Blanchet C, Ludwig C et al. Pseudotumoral-like recur-
rence of visceral leishmaniasis in a seven-year-old girl. Arch Pediatr
2009; 16 (suppl 2): S129–S131.
60. Alvar J, Canavate C, Gutierrez-Solar B et al. Leishmania and human
immunodeﬁciency virus coinfection: the ﬁrst 10 years. Clin Microbiol
Rev 1997; 10: 298–319.
61. Pasquau F, Ena J, Sanchez R et al. Leishmaniasis as an opportunistic
infection in HIV-infected patients: determinants of relapse and mor-
tality in a collaborative study of 228 episodes in a Mediterreanean
region. Eur J Clin Microbiol Infect Dis 2005; 24: 411–418.
62. Alvar J, Croft S, Olliaro P. Chemotherapy in the treatment and con-
trol of leishmaniasis. Adv Parasitol 2006; 61: 223–274.
63. Bourgeois N, Lachaud L, Reynes J, Rouanet I, Mahamat A, Bastien P.
Long-term monitoring of visceral leishmaniasis in patients with AIDS:
relapse risk factors, value of polymerase chain reaction, and poten-
tial impact on secondary prophylaxis. J Acquir Immune Deﬁc Syndr
2008; 48: 13–19.
64. Bourgeois N, Bastien P, Reynes J, Makinson A, Rouanet I, Lachaud L.
‘Active chronic visceral leishmaniasis’ in HIV-1-infected patients
demonstrated by biological and clinical long-term follow-up of 10
patients. HIV Med 2010; 11: 670–673.
65. Lachaud L, Chabbert E, Dubessay P et al. Value of two PCR meth-
ods for the diagnosis of canine visceral leishmaniasis and the detec-
tion of asymptomatic carriers. Parasitology 2002; 125: 197–207.
66. Martinez P, de la Vega E, Laguna F et al. Diagnosis of visceral leish-
maniasis in HIV-infected individuals using peripheral blood smears.
AIDS 1993; 7: 227–230.
67. Fillola G, Corberand JX, Laharrague PF, Levenes H, Massip P, Recco
P. Peripheral intramonocytic leishmanias in an AIDS patient. J Clin
Microbiol 1992; 30: 3284–3285.
68. Molina R, Lopez-Velez R, Gutierrez-Solar B, Jimenez I, Alvar J. Isola-
tion of Leishmania infantum from the blood of a patient with AIDS
using sandﬂies. Trans R Soc Trop Med Hyg 1992; 86: 516.
69. Mathis A, Deplazes P. PCR and in vitro cultivation for detection of
Leishmania spp. in diagnostic samples from humans and dogs. J Clin
Microbiol 1995; 33: 1145–1149.
70. Nicolas L, Sidjanski S, Colle JH, Milon G. Leishmania major reaches
distant cutaneous sites where it persists transiently while persisting
durably in the primary dermal site and its draining lymph node: a
study with laboratory mice. Infect Immun 2000; 68: 6561–6566.
71. Gradoni L, Gramiccia M. Leishmania infantum tropism: strain geno-
type or host immune status? Parasitol Today 1994; 10: 264–267.
72. Callahan HL, Portal IF, Bensinger SJ, Grogl M. Leishmania spp: tem-
perature sensitivity of promastigotes in vitro as a model for tropism
in vivo. Exp Parasitol 1996; 84: 400–409.
73. Zhang WW, Matlashewski G. Screening Leishmania donovani-speciﬁc
genes required for visceral infection. Mol Microbiol 2010; 77: 505–517.
74. Mougneau E, Bihl F, Glaichenhaus N. Cell biology and immunology
of Leishmania. Immunol Rev 2011; 240: 286–296.
75. Nylen S, Gautam S. Immunological perspectives of leishmaniasis.
J Glob Infect Dis 2010; 2: 135–146.
76. Frank SA, Schmid-Hempel P. Mechanisms of pathogenesis and the
evolution of parasite virulence. J Evol Biol 2008; 21: 396–404.
77. Olivier M, Gregory DJ, Forget G. Subversion mechanisms by which
Leishmania parasites can escape the host immune response: a signal-
ing point of view. Clin Microbiol Rev 2005; 18: 293–305.
78. Silva VM, Larangeira DF, Oliveira PR et al. Enhancement of experi-
mental cutaneous leishmaniasis by Leishmania molecules is dependent
on interleukin-4, serine protease/esterase activity, and parasite and
host genetic backgrounds. Infect Immun 2011; 79: 1236–1243.
79. El-Saﬁ S, Kheir MM, Bucheton B et al. Genes and environment in
susceptibility to visceral leishmaniasis. C R Biol 2006; 329: 863–870.
80. Havelkova H, Badalova J, Svobodova M et al. Genetics of susceptibil-
ity to leishmaniasis in mice: four novel loci and functional heteroge-
neity of gene effects. Genes Immun 2006; 7: 220–233.
81. Ramasawmy R, Menezes E, Magalhaes A et al. The )2518 bp pro-
moter polymorphism at CCL2/MCP1 inﬂuences susceptibility to
mucosal but not localized cutaneous leishmaniasis in Brazil. Infect
Genet Evol 2010; 10: 607–613.
82. Frade AF, Oliveira LC, Costa DL et al. TGFB1 and IL8 gene poly-
morphisms and susceptibility to visceral leishmaniasis. Infect Genet
Evol 2011; 11: 912–916.
83. Ajdary S, Ghamilouie MM, Alimohammadian MH, Riazi-Rad F, Pakzad
SR. Toll-like receptor 4 polymorphisms predispose to cutaneous
leishmaniasis. Microbes Infect 2011; 13: 226–231.
84. Castellucci L, Menezes E, Oliveira J et al. IL6-174 G/C promoter
polymorphism inﬂuences susceptibility to mucosal but not local-
ized cutaneous leishmaniasis in Brazil. J Infect Dis 2006; 194: 519–
527.
85. Sakthianandeswaren A, Foote SJ, Handman E. The role of host
genetics in leishmaniasis. Trends Parasitol 2009; 25: 383–391.
86. Bucheton B, Kheir MM, El-Saﬁ SH et al. The interplay between envi-
ronmental and host factors during an outbreak of visceral leishmani-
asis in eastern Sudan. Microbes Infect 2002; 4: 1449–1457.
87. Bucheton B, Abel L, El-Saﬁ S et al. A major susceptibility locus on
chromosome 22q12 plays a critical role in the control of kala-azar.
Am J Hum Genet 2003; 73: 1052–1060.
88. Bucheton B, Abel L, Kheir MM et al. Genetic control of visceral
leishmaniasis in a Sudanese population: candidate gene testing indi-
cates a linkage to the NRAMP1 region. Genes Immun 2003; 4: 104–
109.
89. Alimohammadian MH, Darabi H, Ajdary S, Khaze V, Torkabadi E.
Genotypically distinct strains of Leishmania major display diverse clini-
cal and immunological patterns in BALB/c mice. Infect Genet Evol
2010; 10: 969–975.
90. Swenerton RK, Zhang S, Sajid M et al. The oligopeptidase B of Leish-
mania regulates parasite enolase and immune evasion. J Biol Chem
2011; 286: 429–440.
91. Murray AS, Lynn MA, McMaster WR. The Leishmania mexicana A600
genes are functionally required for amastigote replication. Mol Bio-
chem Parasitol 2010; 172: 80–89.
92. Hide M, Ban˜uls AL. Polymorphisms of cpb multicopy genes in the
Leishmania (Leishmania) donovani complex. Trans R Soc Trop Med Hyg
2008; 102: 105–106.
93. Hide M, Bras-Goncalves R, Ban˜uls AL. Speciﬁc cpb copies within the
Leishmania donovani complex: evolutionary interpretations and
potential clinical implications in humans. Parasitology 2007; 134: 379–
389.
94. Dujardin JC, Ban˜uls AL, Victoir K et al. From population to genome:
ecogenetics of Leishmania (Viannia) braziliensis and L. (V.) peruviana.
Ann Trop Med Parasitol 1995; 89 (suppl 1): 45–53.
95. Peacock CS, Seeger K, Harris D et al. Comparative genomic analysis
of three Leishmania species that cause diverse human disease. Nat
Genet 2007; 39: 839–847.
96. Smith DF, Peacock CS, Cruz AK. Comparative genomics: from
genotype to disease phenotype in the leishmaniases. Int J Parasitol
2007; 37: 1173–1186.
CMI Ban˜uls et al. Leishmaniases and clinical pleiomorphism 1459
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1451–1461
97. Lynn MA, McMaster WR. Leishmania: conserved evolution—diverse
diseases. Trends Parasitol 2008; 24: 103–105.
98. Clayton CE. Life without transcriptional control? From ﬂy to man
and back again. EMBO J 2002; 21: 1881–1888.
99. Hitchcock RA, Thomas S, Campbell DA, Sturm NR. The promoter
and transcribed regions of the Leishmania tarentolae spliced leader
RNA gene array are devoid of nucleosomes. BMC Microbiol 2007; 7:
44.
100. Bates PA. Transmission of Leishmania metacyclic promastigotes by
phlebotomine sand ﬂies. Int J Parasitol 2007; 37: 1097–1106.
101. Kamhawi S. The biological and immunomodulatory properties of
sand ﬂy saliva and its role in the establishment of Leishmania infec-
tions. Microbes Infect 2000; 2: 1765–1773.
102. Rohousova I, Volf P. Sand ﬂy saliva: effects on host immune
response and Leishmania transmission. Folia Parasitol (Praha) 2006; 53:
161–171.
103. Rogers ME, Corware K, Muller I, Bates PA. Leishmania infantum
proteophosphoglycans regurgitated by the bite of its natural sand ﬂy
vector, Lutzomyia longipalpis, promote parasite establishment in mouse
skin and skin-distant tissues. Microbes Infect 2010; 12: 875–879.
104. Ives A, Ronet C, Prevel F et al. Leishmania RNA virus controls the
severity of mucocutaneous leishmaniasis. Science 2011; 331: 775–
778.
105. de La Llave E, Lecoeur H, Besse A, Milon G, Prina E, Lang T. A
combined luciferase imaging and reverse transcription polymerase
chain reaction assay for the study of Leishmania amastigote burden
and correlated mouse tissue transcript ﬂuctuations. Cell Microbiol
2011; 13: 81–91.
106. Prina E, Roux E, Mattei D, Milon G. Leishmania DNA is rapidly
degraded following parasite death: an analysis by microscopy and
real-time PCR. Microbes Infect 2007; 9: 1307–1315.
107. Oliva G, Scalone A, Foglia Manzillo V et al. Incidence and time
course of Leishmania infantum infections examined by parasitological,
serologic, and nested-PCR techniques in a cohort of naive dogs
exposed to three consecutive transmission seasons. J Clin Microbiol
2006; 44: 1318–1322.
108. Martinez V, Quilez J, Sanchez A, Roura X, Francino O, Altet L.
Canine leishmaniasis: the key points for qPCR result interpretation.
Parasit Vectors 2011; 4: 57.
109. Monecke S, Luedicke C, Slickers P, Ehricht R. Molecular epidemiol-
ogy of Staphylococcus aureus in asymptomatic carriers. Eur J Clin
Microbiol Infect Dis 2009; 28: 1159–1165.
110. Sitki-Green D, Covington M, Raab-Traub N. Compartmentalization
and transmission of multiple Epstein–Barr virus strains in asymptom-
atic carriers. J Virol 2003; 77: 1840–1847.
111. Singh BB, Sharma R, Sharma JK, Juyal PD. Parasitic zoonoses in India:
an overview. Rev Sci Tech 2011; 29: 629–637.
112. Harris I, Sharrock WW, Bain LM et al. A large proportion of asymp-
tomatic Plasmodium infections with low and sub-microscopic parasite
densities in the low transmission setting of Temotu Province, Solo-
mon Islands: challenges for malaria diagnostics in an elimination set-
ting. Malar J 2010; 9: 254.
113. Costa CH, Stewart JM, Gomes RB et al. Asymptomatic human carri-
ers of Leishmania chagasi. Am J Trop Med Hyg 2002; 66: 334–337.
114. Courtenay O, Quinnell RJ, Garcez LM, Shaw JJ, Dye C. Infectious-
ness in a cohort of Brazilian dogs: why culling fails to control vis-
ceral leishmaniasis in areas of high transmission. J Infect Dis 2002;
186: 1314–1320.
115. Vieira J, Coelho G. Leishmaniose visceral ou calazar: aspectos
epidemiolo´gicos e de controle. Rev Soc Bras Med Trop 1998; 31(suppl
II): 85–92.
116. Dietze R, Barros GB, Teixeira L et al. Effect of eliminating seroposi-
tive canines on the transmission of visceral leishmaniasis in Brazil.
Clin Infect Dis 1997; 25: 1240–1242.
117. Molina R, Amela C, Nieto J et al. Infectivity of dogs naturally infected
with Leishmania infantum to colonized Phlebotomus perniciosus. Trans
R Soc Trop Med Hyg 1994; 88: 491–493.
118. Moshfe A, Mohebali M, Edrissian G et al. Canine visceral leishmania-
sis: asymptomatic infected dogs as a source of L. infantum infection.
Acta Trop 2009; 112: 101–105.
119. Lima LV, Carneiro LA, Campos MB et al. Canine visceral leishmania-
sis due to Leishmania (L.) infantum chagasi in Amazonian Brazil: com-
parison of the parasite density from the skin, lymph node and
visceral tissues between symptomatic and asymptomatic, seroposi-
tive dogs. Rev Inst Med Trop Sao Paulo 2010; 52: 259–266.
120. Lainson R, Shaw JJ. Evolution, classiﬁcation and geographical distribu-
tion. In: Peters W, Killick-Kendrick R, eds. The leishmaniases in biol-
ogy and medicine. London: Academic Press, 1987; 1–120.
121. Biglino A, Bolla C, Concialdi E, Trisciuoglio A, Romano A, Ferroglio
E. Asymptomatic Leishmania infantum infection in an area of north-
western Italy (Piedmont region) where such infections are tradition-
ally nonendemic. J Clin Microbiol 2010; 48: 131–136.
122. Le Fichoux Y, Quaranta JF, Aufeuvre JP et al. Occurrence of Leish-
mania infantum parasitemia in asymptomatic blood donors living in
an area of endemicity in southern France. J Clin Microbiol 1999; 37:
1953–1957.
123. Riera C, Fisa R, Udina M, Gallego M, Portus M. Detection of Leish-
mania infantum cryptic infection in asymptomatic blood donors living
in an endemic area (Eivissa, Balearic Islands, Spain) by different diag-
nostic methods. Trans R Soc Trop Med Hyg 2004; 98: 102–110.
124. Alborzi A, Pourabbas B, Shahian F, Mardaneh J, Pouladfar GR, Ziyae-
yan M. Detection of Leishmania infantum kinetoplast DNA in the
whole blood of asymptomatic individuals by PCR-ELISA and compar-
ison with other infection markers in endemic areas, southern Iran.
Am J Trop Med Hyg 2008; 79: 839–842.
125. Mary C, Faraut F, Drogoul MP et al. Reference values for Leishmania
infantum parasitemia in different clinical presentations: quantitative
polymerase chain reaction for therapeutic monitoring and patient
follow-up. Am J Trop Med Hyg 2006; 75: 858–863.
126. Garcia-Garcia JA, Martin-Sanchez J, Gallego M et al. Use of noninva-
sive markers to detect Leishmania infection in asymptomatic human
immunodeﬁciency virus-infected patients. J Clin Microbiol 2006; 44:
4455–4458.
127. Scarlata F, Vitale F, Saporito L et al. Asymptomatic Leishmania infan-
tum/chagasi infection in blood donors of western Sicily. Trans R Soc
Trop Med Hyg 2008; 102: 394–396.
128. Colomba C, Saporito L, Vitale F et al. Cryptic Leishmania infantum
infection in Italian HIV infected patients. BMC Infect Dis 2009; 9: 199.
129. Singh SP, Picado A, Boelaert M et al. The epidemiology of Leishmania
donovani infection in high transmission foci in India. Trop Med Int
Health 2010; 15 (suppl 2): 12–20.
130. Reale S, Maxia L, Vitale F, Glorioso NS, Caracappa S, Vesco G.
Detection of Leishmania infantum in dogs by PCR with lymph node
aspirates and blood. J Clin Microbiol 1999; 37: 2931–2935.
131. Solano-Gallego L, Morell P, Arboix M, Alberola J, Ferrer L. Preva-
lence of Leishmania infantum infection in dogs living in an area of
canine leishmaniasis endemicity using PCR on several tissues and
serology. J Clin Microbiol 2001; 39: 560–563.
132. Berrahal F, Mary C, Roze M et al. Canine leishmaniasis: identiﬁcation
of asymptomatic carriers by polymerase chain reaction and immuno-
blotting. Am J Trop Med Hyg 1996; 55: 273–277.
133. Quinnell RJ, Courtenay O, Davidson S et al. Detection of Leishmania
infantum by PCR, serology and cellular immune response in a cohort
study of Brazilian dogs. Parasitology 2001; 122: 253–261.
134. Aoun O, Mary C, Roqueplo C et al. Canine leishmaniasis in south-
east of France: screening of Leishmania infantum antibodies (western
blotting, ELISA) and parasitaemia levels by PCR quantiﬁcation. Vet
Parasitol 2009; 166: 27–31.
1460 Clinical Microbiology and Infection, Volume 17 Number 10, October 2011 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1451–1461
135. Moreno EC, Goncalves AV, Chaves AV et al. Inaccuracy of enzyme-
linked immunosorbent assay using soluble and recombinant antigens
to detect asymptomatic infection by Leishmania infantum. PLoS Negl
Trop Dis 2009; 3: e536.
136. Silveira FT, Lainson R, Pereira EA et al. A longitudinal study on the
transmission dynamics of human Leishmania (Leishmania) infantum
chagasi infection in Amazonian Brazil, with special reference to its
prevalence and incidence. Parasitol Res 2009; 104: 559–567.
137. Lachaud L, Marchergui-Hammami S, Chabbert E, Dereure J, Dedet
JP, Bastien P. Comparison of six PCR methods using peripheral
blood for detection of canine visceral leishmaniasis. J Clin Microbiol
2002; 40: 210–215.
138. Cardo LJ. Leishmania: risk to the blood supply. Transfusion 2006; 46:
1641–1645.
139. Dey A, Singh S. Transfusion transmitted leishmaniasis: a case report
and review of literature. Indian J Med Microbiol 2006; 24: 165–170.
140. Cohen C, Corazza F, De Mol P, Brasseur D. Leishmaniasis acquired
in Belgium. Lancet 1991; 338: 128.
141. Singh S, Chaudhry VP, Wali JP. Transfusion-transmitted kala-azar in
India. Transfusion 1996; 36: 848–849.
142. de Freitas E, Melo MN, da Costa-Val AP, Michalick MS. Transmission
of Leishmania infantum via blood transfusion in dogs: potential for
infection and importance of clinical factors. Vet Parasitol 2006; 137:
159–167.
143. Brouard C, De Valk H, Pilloneln J. Quantitative estimation of the risk
of blood donation infection by infectious agents. Paris: French Institute
for Public Health Surveillance (InVS), 2007.
144. Riera C, Fisa R, Lopez-Chejade P et al. Asymptomatic infection by
Leishmania infantum in blood donors from the Balearic Islands
(Spain). Transfusion 2008; 48: 1383–1389.
145. Cardo LJ, Rentas FJ, Ketchum L et al. Pathogen inactivation of Leish-
mania donovani infantum in plasma and platelet concentrates using
riboﬂavin and ultraviolet light. Vox Sang 2006; 90: 85–91.
146. Oliveira RA, Silva LS, Carvalho VP et al. Visceral leishmaniasis after
renal transplantation: report of 4 cases in northeastern Brazil. Trans-
pl Infect Dis 2008; 10: 364–368.
147. Weisser M, Khanlari B, Terracciano L et al. Visceral leishmaniasis: a
threat to immunocompromised patients in non-endemic areas? Clin
Microbiol Infect 2007; 13: 751–753.
148. Pittalis S, Nicastri E, Spinazzola F et al. Leishmania infantum leishmani-
asis in corticosteroid-treated patients. BMC Infect Dis 2006; 6: 177.
149. Marty P, Izri A, Ozon C et al. A century of leishmaniasis in Alpes-
Maritimes, France. Ann Trop Med Parasitol 2007; 101: 563–574.
150. Minodier P, Piarroux R, Garnier JM, Unal D, Perrimond H, Dumon
H. Pediatric visceral leishmaniasis in southern France. Pediatr Infect
Dis J 1998; 17: 701–704.
151. Khalil EA, Zijlstra EE, Kager PA, El Hassan AM. Epidemiology and
clinical manifestations of Leishmania donovani infection in two villages
in an endemic area in eastern Sudan. Trop Med Int Health 2002; 7:
35–44.
152. El-Saﬁ S, Bucheton B, Kheir MM et al. Epidemiology of visceral
leishmaniasis in Atbara River area, eastern Sudan: the outbreak of
Barbar El Fugara village (1996–1997). Microbes Infect 2002; 4: 1439–
1447.
153. Ibrahim ME, Lambson B, Yousif AO et al. Kala-azar in a high trans-
mission focus: an ethnic and geographic dimension. Am J Trop Med
Hyg 1999; 61: 941–944.
CMI Ban˜uls et al. Leishmaniases and clinical pleiomorphism 1461
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1451–1461
